Status:
COMPLETED
Prophylactic Efficacy of Relenza Against Influenza A and B
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Bronchospasm
Eligibility:
All Genders
Brief Summary
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS ...
Detailed Description
\*\*\*Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to ...
Eligibility Criteria
Inclusion
- 5 years or older
- At least 6 months of continuous follow up time
- Received Relenza without a diagnosis of influenza
Exclusion
- Sex unknown
- Year of birth is missing
- Date of dispensing or service date preceded the year of birth
- Age at index date is less than 5 years
- Not enrolled in the health plan for 6 months prior to the study entry date
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
171705 Patients enrolled
Trial Details
Trial ID
NCT01156701
Start Date
July 1 2009
End Date
May 1 2010
Last Update
May 30 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.